CHROMADEX CORPORATION (NASDAQ:CDXC) Files An 8-K Other Events

CHROMADEX CORPORATION (NASDAQ:CDXC) Files An 8-K Other Events
Item 8.01 Other Events.

As previously disclosed, on December 29, 2016, ChromaDex, Inc. filed a complaint in the United States District Court for the Central District of California, naming Elysium Health, Inc. (together with Elysium Health, LLC, “Elysium”) as defendant (the “Complaint”). On January 25, 2017, Elysium filed an answer and counterclaims in response to the Complaint (together with the Complaint, the “California Action”). The court previously set a jury trial to begin on October 22, 2019.
On August 18, 2019, the parties filed motions for partial summary judgment as to certain claims and counterclaims. The parties filed opposition briefs on August 28, 2019, and reply briefs on September 4, 2019. On October 9, 2019, among other things, the Court ordered supplemental briefing with respect to certain issues related to summary judgment, set the motion hearing date for January 13, 2020, and vacated the October 22, 2019 trial date.
About CHROMADEX CORPORATION (NASDAQ:CDXC)

Story continues below

Chromadex Corporation and its subsidiaries ChromaDex, Inc., ChromaDex Analytics, Inc. and Spherix Consulting, Inc. provide research and quality-control products and services to the natural products industry. The Company allows its business units to discover, acquire, develop and commercialize ingredient technologies that address the dietary supplement, food, beverage, skin care and pharmaceutical markets. The Company operates through three segments: Ingredients, which develops, supplies and commercializes ingredient technologies; Core standards and contract services, which supplies phytochemical reference standards, which are small quantities of plant-based compounds used to research an array of attributes, reference materials and related contract services, and Scientific and regulatory consulting, which provides scientific and regulatory consulting to the clients in the food, supplement and pharmaceutical industries to manage health and regulatory risks.

An ad to help with our costs